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Activation of a number of classAGprotein-coupled receptors
(GPCRs) is thought to involve twomolecular switches, a rotamer
toggle switch within the transmembrane domain and an ionic
lock at the cytoplasmic surface of the receptor; however, the
mechanism by which agonist binding changes these molecular
interactions is not understood. Importantly, 80% of GPCRs
including free fatty acid receptor 1 (FFAR1) lack the comple-
ment of amino acid residues implicated in either or both of these
two switches; the mechanism of activation of these GPCRs is
therefore less clear. By homology modeling, we identified two
Glu residues (Glu-145 and Glu-172) in the second extracellular
loop of FFAR1 that form putative interactions individually
with two transmembrane Arg residues (Arg-183(5.39) and
Arg-258(7.35)) to create two ionic locks. Molecular dynamics
simulations showed that binding of agonists to FFAR1 leads
to breakage of these Glu-Arg interactions. In mutagenesis
experiments, breakage of these two putative interactions by
substituting Ala for Glu-145 and Glu-172 caused constitutive
receptor activation. Our results therefore reveal a molecular
switch for receptor activation present on the extracellular
surface of FFAR1 that is broken by agonist binding. Similar
ionic locks between the transmembrane domains and the
extracellular loops may constitute a mechanism common to
other class A GPCRs also.
G protein-coupled receptors (GPCRs)3 are important com-
ponents of signal transduction machineries that regulate many
physiological processes. They are also important as targets for
therapeutic agents; a large percentage of drugs in the market-
place areGPCR ligands ormodulators. Knowledge of structure-
function relationships ofGPCRs has been gained throughmany
pharmacological, biochemical, and biophysical studies, and has
been used extensively to enhance the discovery of GPCR
ligands that have been developed into therapeutically useful
agents (1–3). Knowledge of the molecular details of ligand-re-
ceptor interaction and of the mechanism of receptor activation
will also likely improve efforts to identify agonists with better
potency and efficacy. Tan et al. (3) have recently reported their
design of agonists with higher potency and efficacy for the trace
amine receptor 1 based on the rotamer toggle switch model of
receptor activation that is thought to operate in a number of
classAGPCRs. The rotamer toggle switch typically involves the
aromatic residues Trp and Phe within transmembrane helix 6
(TMH6) of GPCRs. During agonist-mediated receptor activa-
tion or in constitutively active receptors, the dihedral angle on
the side chain of these residues is predicted to be rotated com-
pared with the inactive state and thereby triggers a movement
of TMH6 away from TMH3 (e.g. Ref. 4). It is also thought that
an ionic lock between an Arg residue in TMH3 and a Glu in
TMH6 near the cytoplasmic surface of some GPCRs holds the
receptor in the inactive conformation and that receptor activa-
tion is accompanied by breakage of the ionic bondwhen agonist
binds; the ionic lock may also be broken by receptor mutation
(e.g. Ref. 5). Although these models of receptor activation have
been proposed for a number of class A GPCRs, it is not certain
how generally this hypothesis can be applied across all mem-
bers of thisGPCRclass. From the alignment of 372 sequences of
humanGPCRs, we noted that about 80% of GPCRs do not have
the putative residues that play a role in either the rotamer toggle
switch, the ionic lock, or both. For these receptors, the interac-
tion responsible for regulating interconversion between inac-
tive and active receptor conformations therefore remains
unknown.
The free fatty acid receptor 1 (FFAR1) is a Gq-coupled, class
AGPCR-activated endogenously by free fatty acids, with a pref-
erence formedium-to-long chain fatty acids (C8–12) (reviewed
in Ref. 6). The receptor has been suggested to be a potential
target for treatment of type 2 diabetes, as offered by the action
of agonists to potentiate glucose-stimulated insulin release
(reviewed in Refs. 7, 8). Several groups, including ours, have
reported the discovery of novel small molecule ligands for
FFAR1 (9–13). Most of these compounds were identified by
high-throughput screening followed by chemical optimiza-
tion (10–12). Our group has delineated the ligand-binding
pocket of FFAR1 (14, 15) and used the information as a ratio-
nal approach to ligand discovery by means of virtual screen-
ing (13). The mechanism of FFAR1 activation; however,
remains unknown especially because this receptor does not
contain either the rotamer toggle switch or the ionic lock
between TMHs 3 and 6.
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We have previously identified nine residues in the ligand-
binding pocket of FFAR1 that are important for ligand recog-
nition and/or receptor activation (14). In particular, two Arg
residues (Arg-183(5.39)4 and Arg-258(7.35)) and an Asn resi-
due (Asn-244(6.55)) in the TMHs coordinate the carboxylate
head group of the naturally occurring agonist linoleate and the
synthetic agonist GW9508. In the present study, by a collabo-
rative effort using computational modeling and receptor
mutagenesis, we report the identification of Glu-172 in the sec-
ond extracellular loop (ECL2) of FFAR1 that may function
together with Arg-183(5.39) and Arg-258(7.35) as locks to con-
trol activation of the receptor. Our results suggest that these
ionic locks at the extracellular surface hold the receptor in an
inactive state. Agonists, through interaction with the arginine
residues, may break the arginine-glutamate interactions
thereby allowing the receptor to adopt an active conformation.
Therefore, our results have provided insights into the mecha-
nism of activation of class A GPCRs that function in a manner
not explicable by the more well-studied models.
MATERIALS ANDMETHODS
Construction of theModels of the Receptor-LigandComplexes—
Amodel of FFAR1 was constructed based on the 2-adrenergic
receptor (2AR)(PDB ID: 2rh1) using MODELLER (16) as
implemented in Insight II.5 The optimization procedure, using
the Discovery module of Insight II,5 consisted of 5000 steps of
conjugated gradient energy minimization and 1000 steps of
molecular dynamics (MD) with distance constraints for the
atoms involved in interhelical hydrogen bonding in the back-
bone of the transmembrane domains. The interatomic distance
between the atoms involved in the formation of hydrogen
bondswas set at 2.5Å, and the force of the constraintswas set to
1000 kcal/mol/Å. A distance-dependent dielectric constant
was applied. Linoleate and GW9508 were docked to the novel
model of FFAR1 by superimposing the previously defined
model of the ligand-receptor complex constructed on the basis
of rhodopsin (15). The novel complexes were subjected to 1000
steps of conjugate gradient energy minimization, also per-
formed with the Discovery module of Insight.
MD Simulations—MD simulations were conducted using
CHARMM (version c33b2) (18). Simulations were performed
in implicitmembrane using theGeneralized Bornwith a simple
switching (GBSW) (19, 20) method implemented CHARMM.
The charges for linoleate and GW9508, and dihedral angle
parameters for GW9508 were obtained using Hartree-Fock/
G31** calculations in Gaussian.6 Langevin simulations were
performed at a temperature of 300 K with a time-step of 0.002
ps. The empty or linoleate/GW9508-occupied FFAR1 struc-
tures were first energy-minimized for 200 steps using the
adopted basis set Newton Raphson (ABNR) minimizer and
then subjected to 3.5-ns MD simulations. During the simula-
tions, to preserve the helical structures of the transmembrane
domains, nuclear Overhauser enhancement (NOE) restraints
were applied to the distances between the backbone carbonylO
of residue n and the backbone NH of residue n4, setting
FMAX and KMAX to 200.0 and 80.0 kcal/mol/Å, respectively.
Receptor Plasmids and Site-directed Mutagenesis—A plas-
mid coding for wild-type FFAR1 was cloned into
pcDNA3.1/hygro() (Invitrogen) as reported previously (14).
Site-directed mutagenesis was performed using the
QuikChange II XL mutagenesis kit (Stratagene). Sequences on
the promoter and the full insert in all constructs were verified
by sequencing (MWG Biotech).
Cell Culture and Transfection—Cells were seeded at 18,400/
well in 96-well plates 1 day prior to transfection. CHO-K1 cells
were maintained in F-12 medium supplemented with 10% fetal
bovine serum. HEK-EM (293) cells (22) were maintained in
DMEM medium supplemented with 10% fetal bovine serum.
Transfection was carried out using Lipofectamine LTX
(Invitrogen) according to themanufacturer’s recommendation.
For the reporter gene assay, the PathDetect in vivo trans-re-
porting system (Stratagene) was used. The trans-reporting sys-
tem utilizing the ERK1/2 pathway was used in CHO-K1 cells.
Cells were co-transfected per well with 48 ng of receptor/lacZ
control plasmid, 48 ng of pFR-Luc plasmid, and 2 ng of pFA2-
Elk1 trans-activator plasmid. For the cis-reporting system, cells
were co-transfected per well with 50 ng of receptor/lacZ con-
trol plasmid and 50 ng of pAP-1-Luc plasmid.
Cytoplasmic Free Ca2 Concentration ([Ca2]i) Measure-
ment—Measurement of [Ca2]i was made by loading FFAR1-
expressing HEK-EM (293) cells with Calcium4 reagent (Molec-
ular Devices) and monitoring the changes in fluorescence
intensity upon agonist stimulation with the FLIPR (Molecular
Devices, Sunnyvale, CA), as described previously (14). Assays
were performed in quadruplicate.
Reporter Gene Assay—Assay for reporter gene activity was
carried out by washing transfected cells with the corresponding
serum-free medium and incubating them in serum-free
medium supplementedwith 1mM fatty acid-free BSA.The fatty
acid-free BSAwas used to bind endogenously released free fatty
acids, in light of the report by Stoddart et al. (23). Nevertheless,
further experimentation in the absence or presence of 1 nM to 3
mM fatty acid-free BSA to adsorb endogenously released FFAs
showed that endogenously released FFAdoes not interferewith
the system under study. Cells were frozen at 20 °C after a
further 22-h incubation. Luciferase activity was measured fol-
lowing thawing and lysis of cells with 100 l/well lysis buffer.
The entire cell lysate was combined with 125 l of reaction
buffer and 25 l of 0.4 mM luciferin (Sigma) automatically via
automatic injectors in Victor3 multi-label reader (PerkinElmer
Life Sciences). The composition of the lysis buffer and reaction
buffer has been reported previously (24). Luminescence was
measured for 3 s after shaking for 2 s.
Measurement of Expression Levels ofWT, E145A, and E172A—
FLAG epitope-tagged receptors were analyzed by flow
cytometry in a FACSCalibur (BectonDickinson). FLAG-recep-
tor-expressing HEK-EM (293) cells were labeled with FITC-
conjugated anti-FLAGM2 antibodies (Sigma) according to our
previously described protocol (14). Levels of surface receptors
were quantified as the mean fluorescence signal and normal-
ized as a percentage of the wild-type receptor level.
4 Residues are identified through the indexing system of Ballesteros and
Weinstein (17); see legend of Fig. 1 for details.
5 Insight II, Version 2001, (2006) Accelrys Inc.
6 Gaussian 03, Revision C. 02. (2004) Gaussian, Inc., Wallingford, CT.
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RESULTS
While the activation of a number of class A GPCRs is postu-
lated to involve the rotamer toggle switch or the breakage of an
ionic lock at the cytoplasmic surface, or both, we noted that
FFAR1 does not contain the complement of amino acid resi-
dues required to form the putative switches (Fig. 1). At the
location in FFAR1 of the putative rotamer toggle switch, a Val
and Asn are present at 6.48 and 6.52, respectively, instead of
aromatic acid residues. And, in the region of the putative ionic
lock at the cytoplasmic surface of FFAR1, a Lys is present at 6.30
rather than a Glu, and its nearby residues are ones with hydro-
phobic side chains or are Arg residues. It is therefore unlikely
that these residues regulate receptor activation in the same
manner as described by the postulated models. It is possible,
however, that a similar ionic lock may be present at a different
location in the receptor.
We therefore performed a search for putative ionic interac-
tions using an improved FFAR1 homologymodel. Our previous
model was constructed in the absence of ECL2 and was based
on the crystal structure of rhodopsin. Given the recent avail-
ability of a 2.4-Å structure of 2AR (25, 26), we reconstructed a
new FFAR1model based on this template because of the closer
sequence identity of FFAR1 with 2AR than with rhodopsin
(28% versus 16%). In the 2AR structure, the TMHs are more
tilted away from the center of the receptor than in the structure
of rhodopsin. Moreover, in the 2AR structure, ECL2 forms a
short helix instead of the  hairpin present in rhodopsin and,
unlike in rhodopsin, does not occlude the ligand-binding cavity.
In this regard, the 2AR may be more representative of the
typical GPCRs, which in the majority of cases are activated by
diffusible ligands. The ECL2 of rho-
dopsin in not an ideal template for
the construction ofGPCRmodels as
it is deeply buried into the trans-
membrane cavity and would hinder
ligand docking (27). When dealing
with rhodopsin-based models, sig-
nificantly better results have been
obtained modeling ECL2 de novo
(27), removing ECL2 and expand-
ing the ligand-binding pocket
through conformational searches
prior to docking (15), or guiding the
docking by means of constraints
based on mutagenesis data (28, 29).
Because of the larger volume of the
binding pocket and to the solvent-
exposed conformation of ECL2, a
2AR-based homology model
might be suitable for ligand docking
with minimal or no optimization.
In our new FFAR1 model, the
TMHs were constructed based on
the 2AR, while the extracellular
and intracellular loops were mod-
eled de novo by means of the algo-
rithm implemented in MODELLER
(16). We imposed the formation of
the disulfide bridge between two conserved Cys residues
located in ECL2 and TMH3, and, among a total of 20 generated
loop models, chose the ECL2 conformation that most closely
resembled that seen in the 2AR structure, based on root-mean
square deviation in the backbone of the ECL2-(170–182) portion.
Notably, in our new 2AR-based model, Glu-145(ECL2)forms a
putative hydrogen bond with Arg-183(5.39), and Glu-172(ECL2)
formsahydrogenbondwithArg-283(7.35) (Fig. 2A). It isnotewor-
thy that Glu-145(ECL2) faces the binding pocket in the current
model, whereas it pointed away from the transmembrane core in
our previous rhodopsin-based homologymodel.
MDSimulations of Unoccupied andAgonist-occupied FFAR1—
Because Arg-183(5.39) and Arg-258(7.35) may form putative
hydrogen bonds with Glu-145(ECL2)and Glu-172(ECL2) on
the one hand, and with the carboxylate group of an agonist on
the other hand (14), we wanted to examine the dynamic prop-
erties of these networks of Arg-Glu interactions in relation to
agonist occupancy. To study the interactions between the two
Arg-Glu pairs, wemonitored the non-bonded interaction ener-
gies, including electrostatic and van der Waals components,
along the MD trajectories in the unoccupied or agonist-occu-
pied FFAR1 (Fig. 3). The simulations were carried out for 3.5 ns
using Langevin dynamics with an implicit membrane model.
After about 1 ns, the systems reached and maintained a stable
conformation, as indicated by the root mean square deviation
of the FFAR1 backbone calculated from the average structure
obtained over the period of 1–3.5-ns simulations (supplemen-
tal Fig. S1). Throughout the simulations, the interaction ener-
gies between Glu and Arg residues in the unoccupied receptor
remained constant, indicating that their interactions were sta-
FIGURE 1. Sequence alignment of FFAR1, rhodopsin, and 2-adrenergic receptor. The most conserved
residues in each transmembrane domain are labeled as X.50, according to the Ballesteros and Weinstein
nomenclature (17). Symbols indicatepositions of residuesbelieved tobe involved in the rotamer toggle switch
(#) and the ionic lock (*) between the cytosolic ends of TM3 and TM6. Residues forming ionic locks between the
TM helical bundle and ECL2 of FFAR1 are colored in red and blue.
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ble and strong. Specifically, the carboxylate groups of Glu-
145(ECL2) and Glu-172(ECL2) formed ionic interactions with
Arg-183(5.39) and Arg-258(7.35), respectively. When FFAR1
was complexed with either linoleate or GW9508, the ligand
competed via its carboxylate group for the interaction with the
Arg residues. The ligand-receptor interactions remained stable
and the ligands retained their initial conformations over the
course of the simulations. In contrast, the interaction energy
between Arg-183(5.39) and Glu-145(ECL2) became signifi-
cantly weaker during the simulations (Fig. 3A). A weaker inter-
action energy was also observed between Arg-258(7.35) and
Glu-172(ECL2) (Fig. 3B). The weaker interaction energies
between the two Arg-Glu pairs in the agonist-occupied recep-
tor suggest that the presence of agonist perturbs these ionic
locks. The average structures of FFAR1 in complex with linole-
ate and GW9508 calculated over the period of 1–3.5-ns simu-
lations are shown in Fig. 2 (B and C).
Constitutive Activation of Receptor through Mutation—The
results of theMDsimulations suggested that theArg-Glumight
be a part of the molecular switch that governs receptor activa-
tion through an exchange of interacting partners with an ago-
nist. We therefore hypothesized that the Arg-Glu interactions
in the unliganded receptor function as locks that keep the
receptor in the inactive state and agonists activate the receptor
by weakening or breaking these interactions. Following this
rationale, we postulated thatmutations that prevent the forma-
tion of these interactions would lead to constitutive activation.
We addressed this idea by constructing individual Ala mutants
of Glu-145(ECL2) and Glu-172(ECL2) in FFAR1 and deter-
FIGURE 2.Molecularmodels of the unoccupied FFAR1 and FFAR1 com-
plexed with linoleate or GW9508. The salt bridges between amino acid
residues Glu-145(ECL2) and Arg-183(5.39) and Glu-172(ECL2) and
Arg-258(7.35) are identified in unoccupied FFAR1 (A) and in FFAR1 com-
plexed with linoleate (B) or GW9508 (C).
FIGURE 3. Non-bonded interaction energies (van-der-Waals and electro-
static components) between two putative ionic locks. The interaction
energies between Glu-145(ECL2) and Arg-183(5.39) (A) and Glu-172 and Arg-
258(7.35) (B) for the unoccupied FFAR1 (black) and FFAR1 in complex with
linoleate (red) or GW9508 (green) were computed along 3.5-ns trajectories.
The changes in energies are expressed as percent deviation from the average
energy detected for the unoccupied receptor.
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mined their constitutive activities using luciferase-based tran-
scriptional reporter assays. As it has been suggested that the
release of endogenous fatty acid during membrane preparation
may lead to apparent constitutive activity in FFAR1 that can be
reversed by incubation with BSA (23), measurement of consti-
tutive activity in intact cells may avoid such complication. To
further prevent this potential problem, cells were incubated
with serum-free medium supplemented with 1 mM fatty acid-
free BSA during the assay. Agonist-stimulated activities were
assessed by measuring linoleate-stimulated increases in cyto-
plasmic free calcium concentration ([Ca2]i) and constitutive
receptor activities were assessed using a trans-reporter system,
measuring the activation of ERK1/2 pathway using CHO-K1
cells, which is a more sensitive assay of constitutive signaling.
Transfection with wild-type FFAR1 confirmed that linoleate
stimulated a FFAR1-dependent increase in [Ca2]i (Fig. 4A)
and showed that the receptor did not exhibit any measurable
constitutive activity, as reflected by the lack of increased lucif-
erase activity over lacZ-transfected control cells (Fig. 4B). In
contrast, linoleate stimulation of cells expressing E145A or
E172A caused increases in [Ca2]i that were 48 and 33% ofWT,
respectively, whereas these mutant receptors exhibited
increases of constitutive luciferase activities above WT of
3-fold for E145A and 7-fold for E172A. Mutation of Arg-
183(5.39) or Arg-258(7.35) to Ala generated receptors that
exhibited linoleate-stimulated signaling activities of 43 and 48%
ofWT, respectively. R183A exhibited a low level of constitutive
activity of2-fold over basal luciferase whereas R258A did not
exhibit constitutive activity above that of WT. We estimated
the levels of cell-surface expression of E145A and E172A using
FLAG epitope-tagged receptors. FLAG-E145A was expressed
at a level 173 11% (mean S.E.) of WT and FLAG-E172A at
85 5.5% ofWT; we did not construct FLAG-tagged R183A or
R258A. We verified the observed increases in constitutive
activities of E145A and E172A in titration experiments with
increasing amounts of receptor plasmid for transfection.
Increasing doses of wild-type receptor resulted in background
activity that was independent of plasmid level, confirming the
absence of constitutive activity of wild-type FFAR1 (Fig. 5). In
contrast, titrating with increasing amounts of either E145A or
E172A plasmids (Fig. 5) resulted in proportionally higher lucif-
erase activities. The measured constitutive activities were
unlikely due to activation of the mutant receptors by endog-
enously released FFAs because the wild-type receptor showed
no increased signaling over the receptor-negative control cells.
Taken together, the results from this series of experiments sug-
gest that Glu-145(ECL2), Glu-172(ECL2) and Arg-183 con-
strain the receptor in an inactive conformation, consistent with
our hypothesis.
DISCUSSION
Residues in ECL2 have been shown to be important for ago-
nistic activity in a number of GPCRs. In the m3 muscarinic
receptor, several ECL2 amino acids with different physico-
chemical properties have been shown to be important for ago-
nist activity (30). The residues appear to play a role solely in
receptor activation because their mutation negatively affects
potency but not affinity of the agonist carbachol. A role for
ECL2 in guiding thyrotropin-releasing hormone (TRH) into the
transmembrane binding pocket of the TRH receptor type 1 was
hypothesized based on mutagenesis and computational exper-
iments (31, 32). The importance of ECL2 in allowing access of
ligand to receptor was suggested also in the m2 muscarinic
receptor in which the flexibility of the loop was reduced by
creating a mutant that forms an additional disulfide bond (33).
The ECL2 has also been shown to have a role in agonist and
antagonist recognition in the adenosine and P2Y receptors (28,
34–36). In the 5-HT4 receptor, distinct conformational
changes in the ECL2 upon binding to agonists, neutral antago-
nists or inverse agonists were observed in circular dichroic
spectra (37). By alanine-scanningmutagenesis of ECL2 residues
in V1a vasopressin receptor, several aromatic residues in the
receptor were found to be important in maintaining high affin-
ity binding to agonist and a certain class of antagonists and for
potent agonistic activity (38). Furthermore, from a random
mutagenesis study, residues in the ECL2 of C5a receptor were
suggested to formmultiple interactions that stabilize the recep-
tor in the inactive state (39). Based on the results of all of these
FIGURE 4. Signaling activities of FFAR1mutants. A, agonist-stimulated sig-
naling was determined by measuring increases in [Ca2]i in response to
increasing doses of linoleate as described under “Materials and Methods.”
RFU represents the relative fluorescence units of the Calcium4 reagent. Data
shownaremean S.E. of quadruplicate samples in twoexperiments.B, levels
of constitutive activities were determined in CHO-K1 cells by co-transfection
of the receptor plasmid and an Elk1-Gal4 trans-activator element and a lucif-
erase reporter as described under “Materials and Methods.” Data shown are
mean  S.E. after normalizing the luminescence levels relative to wild-type
receptor. One-way analysis of varianceperformed indicated significant differ-
ences among the groups. Subsequently, Newman-Keuls multiple compari-
son test was performed to determine whether luciferase activity was statisti-
cally different from the lacZ (#) or wild-type group (*). ##, p  0.001; #, p 
0.01; **, p 0.001; *, p 0.05.
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studies, it may be suggested that ECL2 can participate in ligand
interaction and appears to contribute to receptor activation,
despite differences in the specific locations and identities of the
functional residues in structurally related GPCRs.
In FFAR1, we have identified two critical residues, Glu-
145(ECL2) and Glu-172(ECL2), in ECL2 that play a role in reg-
ulating receptor function. By a combination of computational
and biological studies, we determined that two key interactions,
salt bridges between Glu-145(ECL2) and Arg-183(5.39) and
betweenGlu-172(ECL2) and Arg-258(7.35), are responsible for
constraining the receptor in an inactive state. The role of these
Glu residues is supported by the decreased agonist-stimulated
and increased constitutive activities of E145A and E172A and
by computational simulations showing that agonists cause sep-
aration of Glu-145(ECL2) and Arg-183(5.39) as well as Glu-
172(ECL2) and Arg-258(7.35). Intuitively, it may be conceived
that mutation of Arg-183(5.39) and Arg-258(7.35) will cause
constitutive activity similar to that caused by mutation of Glu-
145 and Glu-172(ECL2). This was not found to be the case
although modest constitutive activity was observed for R183A.
It is worth noting that mutations of Arg3.50, the residue that
forms one part of the ionic lockwithGlu/Asp6.30 (see below) in
other class A GPCRs, do not always cause constitutive activity
and sometimes decreases constitutive signaling depending on
the receptor (see Ref. 40 for review).
The results from the present study provide us with a mecha-
nistic insight into the activation of FFAR1 and perhaps other
GPCRs. For a number of them, activation is believed to involve
conformational changes of aromatic residues at positions 6.48
and 6.52 and a breakage of the salt bridge formed by Arg3.50
and Glu/Asp6.30. These residues are considered molecular
switches that trigger the conversion of a receptor from the inac-
tive to the active state. A salt bridge between Arg3.50 and
Glu6.30 is observed in the crystal structure of rhodopsin (41). A
number of GPCRs such as the 2AR (5), 1b-adrenergic recep-
tor (42) and 5-hydroxytryptamine receptor (43) show constitu-
tive activity when this salt bridge is disrupted by mutation of
one or both of the interacting partners.However, this activation
model is not applicable to all GPCRs because the residues at
these positions are not conserved among all GPCRs, suggesting
the presence of alternative conformational switches apart from
thesewell known ones. To gauge the generality of the activation
model involving the aromatic toggle switch in TMH6 or the
ionic lock betweenTMH3 andTMH6,we examined a sequence
alignment of 372 human GPCRs belonging to all classes (369
sequences were derived from the analysis reported by Surgand
et al. (44), while three additional sequences were derived from
our previous analysis of the nucleotide and lipid receptor clus-
ter (15)). With regard to the rotamer toggle switch, we found
that 69 sequences do not feature aromatic residues at position
6.48 and 218 do not feature aromatic residues at position 6.52.
In terms of the ionic lock, 90 sequences do not have a positive
charge at position 3.50 of the (D/E)RYmotif and 275 sequences
do not have a negatively charge residue at 6.30. In FFAR1, Val
andAsn are found at positions 6.48 and 6.52, while a Lys residue
is in place of a negatively charged residue at position 6.30.
Therefore, the two most studied molecular switches do not
apply tomanyGPCRs, including FFAR1, and alternativemolec-
ular switches are likely to exist.
In FFAR1, we propose that a part of the activation process
involves the releasing of constraints imposed by the ionic lock
between Arg-183(5.39) and Glu-145(ECL2)and between Arg-
258(7.35) and Glu-172(ECL2). Arg-183(5.39) and Arg-258(7.35)
are located near the extracellular end of TMH5 and TMH7,
respectively. Both Glu-145(ECL2) and Glu-172(ECL2) are
located in ECL2, the former being two positions away from the
end of TMH4 and the latter two positions away from the con-
servedCys of ECL2 that forms a putative disulfide bridge. These
Arg-Glu ionic interactions appear to be important for restrain-
ing the receptor in an inactive conformation because
mutation of Glu-145(ECL2) and Glu-172(ECL2) leads to
constitutive activation. These interactions are weakened
or perhaps broken when an agonist interacts with
Arg-183(5.39) and Arg-258(7.35) that along with Asn-244
function to coordinate the agonist at the head group. We
FIGURE 5. Increased constitutive activities of E172A (A) and E145A (B)
FFAR1 mutants. The levels of constitutive activity were determined as
described under “Materials and Methods.” The amount of receptor plasmid
was titrated at a range of 0–48 ngby varying the amount of receptor plasmid
while keeping the total amount of DNA transfected constant by supplement-
ing themixture with lacZ control plasmid. Data shown aremeans S.E. after
normalizing the data relative to the value obtained with zero receptor plas-
mid in the wild-type data set.
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suggest that this exchange of interacting partners from the
receptor to the agonist for Arg-183(5.39) and Arg-258(7.35)
allows the receptor to adopt an active conformation.
Charged residues are not uncommon in ECL2 of class A
GPCRs, in particular, in the nucleotide and lipid receptor clus-
ter to which FFAR1 belongs. Of 45 sequences in the nucleotide
and lipid receptor cluster, 26 receptors have either a Glu or an
Asp located two positions away from the Cys that forms the
putative disulfide bond, forming a CX(E/D) motif (Glu-
172(ECL2) in FFAR1). In contrast, it is difficult to determine the
residues in other class A GPCRs that correspond to Glu-
145(ECL2)as ECL2 is known to be variable both in length and
sequence. Given the negatively charged nature of nucleotide
and lipid agonists, the negatively charged residues of ECL2 are
not involved in ligand recognition, as they would in fact exert
repulsive forces on the ligands, but are likely to be the counte-
rions of positively charged residues located within the binding
pocket. In linewith this hypothesis, it has been shownbymolec-
ular modeling andmolecular dynamics simulations of the P2Y6
receptor that the negatively charged Asp-179 in ECL2 interacts
with Arg-103(3.29) near the extracellular end of TMH3 (21).
Besides interacting with Asp-179(ECL2), Arg-103(3.29) also
plays a role in coordinating the phosphate group of nucleotide
agonists. In an interesting analogy with FFAR1, coordination of
the agonist by Arg-103(3.29) is accompanied by release of the
Asp-179-Arg-103 interaction resulting in a movement of ECL2
away from the ligand binding cavity (21). In this example, a
positively charged residue located in TM3, not TM7 like in
FFAR1, forms an ionic interaction with a negatively charged
residue located in ECL2, in the position correspondent to Glu-
172 in FFAR1.
Based on the data, we propose that the breakage of the ionic
lock between Glu-145(ECL2)and Arg-183(5.39) or between
Glu-172(ECL2) and Arg-258(7.35) may constitute a part of the
activation mechanism in FFAR1. These two ionic locks might
operate independently because disruption of either one of them
leads to constitutive activity.We suggest thatwhen an agonist is
attracted to the receptor via interaction with Arg-183(5.39) or
Arg-258(7.35), these interactions, which function to keep the
receptor inactive, become weakened and break apart. Accom-
panying this breakage of the ionic lock, ECL2may becomemore
mobile and allow the receptor to adopt a fully activated state.
Two antagonists that we identified (compound 8 and 21 in Ref.
13) contain a less electronegative nitro group instead of a car-
boxyl group which may be unable to release the ionic lock and
activate the receptor. We suggest that the knowledge gained
from this study can be exploited for the design of new FFAR1
agonists and antagonists.
Analyzing the sequences of non-olfactory humanGPCRs, we
found that about half of them have positively charged residues
in the binding pocket.We speculate that some of these residues
may interact with negatively charged residues located in ECL2,
which are also very common, thus forming an ionic lock that
keeps the receptor in an inactive state in the absence of agonist,
but that can be disrupted by agonists. The locking mechanisms
would be similar to the one that we propose for FFAR1; how-
ever the specific locations of the residues within ECL2 and the
TMs may be different.
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